NanoViricides Inc. Shares Approach 52-Week Low - Market Mover
The shares closed 1.7% above its 52-week low of $2.86, with trading volume lower than its 30 day average
Jan 18, 2022 by Kwhen Finance Editors
NanoViricides Inc. (NNVC) shares closed today at 1.7% above its 52 week low of $2.86, giving the company a market cap of $33M. The stock is currently down 21.8% year-to-date, down 11.3% over the past 12 months, and down 88.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%.
Trading Activity
- Trading volume this week was 41.1% lower than the 20-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
- MACD, a trend-following momentum indicator, indicates a downward trend.
- The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance
- The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis
- The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis
- The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| NanoViricides Inc. | -1.4 | -21.8 | -11.3 | -66.4 | 2.4 |
| Dow Jones Industrial Average | -0.6 | -1.2 | 18.5 | -3.1 | 22.0 |
| S&P 500 Index | 0.0 | -2.2 | 25.3 | -3.9 | 26.9 |
| Health Care | -0.2 | -5.7 | 12.6 | -6.8 | 19.8 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date lags the peer average by 1241.6%
- The company's stock price performance over the past 12 months lags the peer average by -526.1%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| NanoViricides Inc. | NNVC | 0 | -21.8 | -11.3 | -66.4 | 2.4 |
| Peer Avg | N/A | 1.0 | -1.6 | 2.6 | -29.3 | 80.7 |
| Merck & Co Inc | MRK | 28.6 | 6.2 | 1.1 | -9.9 | 447.3 |
| Bristol-Myers Squibb Co. | BMY | -26.7 | 5.1 | 0.8 | -5.8 | 22.5 |
| Glaxosmithkline plc - ADR | GSK | 17.6 | 3.1 | 25.0 | -0.8 | 40.5 |
| Gilead Sciences, Inc. | GILD | 12.2 | -1.2 | 18.2 | -2.9 | 22.2 |
| Novavax, Inc. | NVAX | -7.8 | -22.5 | -13.0 | -69.5 | 0.1 |
| Biocryst Pharmaceuticals Inc. | BCRX | -12.2 | 11.8 | 75.9 | -15.0 | 87.6 |
| Chimerix Inc | CMRX | -3.6 | -6.7 | -24.4 | -50.4 | 20.8 |
| NovaBay Pharmaceuticals Inc. | NBY | 0 | -8.7 | -62.4 | -80.4 | 4.8 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: